GI
RNAM

GAMMA Investing’s Avidity Biosciences RNAM Stock Holding History

GAMMA Investing’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,471
Closed -$178K – 4214
2025
Q4 		$178K Buy
2,471
+234
+10% +$15.1K 0.01% 1122
2025
Q3 		$97.5K Buy
2,237
+195
+10% +$7.88K 0.01% 1525
2025
Q2 		$58K Sell
2,042
-203
-9% -$6.05K ﹤0.01% 1833
2025
Q1 		$66.3K Buy
2,245
+277
+14% +$8.63K 0.01% 1589
2024
Q4 		$57.2K Sell
1,968
-11
-0.6% -$460 ﹤0.01% 1553
2024
Q3 		$90.9K Buy
1,979
+106
+6% +$4.6K 0.01% 1068
2024
Q2 		$76.5K Buy
1,873
+8
+0.4% +$230 0.01% 920
2024
Q1 		$47.6K Buy
1,865
+129
+7% +$2.02K 0.01% 1077
2023
Q4 		$21.2K Buy
+1,736
New +$11.6K 0.01% 1465

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

GAMMA Investing's RNAM Position: Q1 2026 in Review

GAMMA Investing sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 2,471 shares — an estimated $178K sold.

GAMMA Investing first reported a position in RNAM in Q4 2023 and held it in 9 quarters. The position peaked at $178K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • GAMMA Investing reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • GAMMA Investing sold 2,471 Avidity Biosciences shares in Q1 2026, an estimated $178K.
  • GAMMA Investing first reported a position in Avidity Biosciences in Q4 2023 and held it in 9 quarters.
  • GAMMA Investing's Avidity Biosciences position peaked at $178K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on GAMMA Investing's 13F filing for Q1 2026, filed 6 Apr 2026.